ArticleBlood neoplasia2025
Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis.
Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.British journal of haematology · 2026Article
- Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment sequencing and survival outcomes in follicular lymphoma (FL) are heterogeneous. This study describes real-world treatment patterns and outcomes among older patients with FL in the United States. Patients aged ≥65 years diagnosed with FL were identified from Surveillance, Epidemiology, and End Results-Medicare (2000-2017) and followed up through 2019. A total of 13 423 patients with FL (median age, 76 years at diagnosis) were included. With a median follow-up of 57.1 months, 38% of patients had no record of initiating any systemic treatment during the observation window; 62%, 23%, 9%, and 4% received ≥1, ≥2, ≥3, and ≥4 lines of therapy (LOTs), respectively. Survival rates increased significantly (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.